DaVita Inc. stock gains on solid Q1 figures and buybacks

DaVita Inc. stock (ISIN US23918K1088) closed at USD 183.98 on the New York Stock Exchange on September 4, 2026, giving the dialysis specialist a market capitalization of USD 11.739 billion according to an ad-hoc-news.de company snapshot as of that date.

Recent earnings and profitability

According to an overview of DaVita compiled by ad-hoc-news.de, the company reported revenue of USD 3.42 billion in the first quarter of fiscal year 2026 (Q1 FY26).

The same snapshot shows Q1 FY26 earnings of USD 197.53 million, which corresponds to a profit margin of 5.78 percent for the period.

Share repurchases and capital allocation

DaVita continues to return capital to shareholders. A summary of market data cited by ad-hoc-news.de notes that DaVita repurchased more than 1.0 million shares for about USD 165.6 million in the second quarter of 2026 (Q2 2026).

The same source points out that DaVita has bought back more than 46.9 million shares in total over its buyback program, illustrating how management has been using free cash flow to reduce the share count over time.

Dialysis services as core business

DaVita Inc. generates the bulk of its revenue by operating dialysis centers for patients with chronic kidney failure, providing regular treatments that are critical for long-term survival.

Stock level and investor view

As of the closing price on September 4, 2026, DaVita Inc. stock stood at USD 183.98 on the NYSE.